The Briefing › Deals

Deals ·

Today’s top deals in AI, energy and biotech: 7 Nov 2026

The Briefing by Christian Soschner

The five deals that mattered most on 7 November 2026 across energy, AI, robotics and biotech, and what each one means, followed by every other verified deal of the day by sector. Every item links to its original source.

  1. Energy & EV financing · US · 5 Nov

    Harbinger raises a $240M Series D to take its EV platform into energy storage and defense

    Tiger Global, Capricorn’s Technology Impact Fund and the defense investor Ridgeline co-led the round. Fidelity, Squarepoint and Xantium joined as crossover investors, Maniv and Greycroft came back, and FedEx and THOR Industries invested as strategic backers. The Los Angeles company now builds on its electric truck platform with energy storage, power generation, autonomy through its acquisition of Phantom AI, and an uncrewed Army supply vehicle with American Rheinmetall. Harbinger has raised more than $650M since 2021.

    Why it matters: FedEx sits on both sides of the table: it ordered 2,000 Harbinger trucks worth more than $300M, due by the end of 2027, and it invests in the round.

    Source: TechCrunch

  2. AI financing · US · 4 Nov

    Traversal raises a $120M Series B at a $1B valuation to find the root cause of production outages

    Kleiner Perkins, Redpoint Ventures and Khosla Ventures co-led the round, with strong participation from Sequoia and Battery Ventures. Traversal’s AI site reliability platform builds a model of a company’s production systems from telemetry, code and deployment history, then tests many causes in parallel to explain an outage. Monthly investigations on the platform grew from 513 to nearly 73,000 this year. The money goes into hiring across research, engineering and sales.

    Why it matters: As AI writes more of the world’s code, keeping that code running in production becomes a market of its own, and Traversal reached a $1B valuation within about 17 months of leaving stealth.

    Source: Traversal

  3. Insurance AI financing · US · 5 Nov

    Kalepa raises a $75M Series B at a $470M valuation to bring AI agents into insurance underwriting

    Updata Partners led the round, and IA Ventures and Inspired Capital, both Series A backers, returned. The New York company’s platform coordinates work across insurance operations, underwriting, pricing and portfolio management, with agents whose autonomy matches the risk of each task and results that can be audited. Kalepa has now raised $91M and plans to roughly double its team in 2027.

    Why it matters: Insurers are among the first to hand core professional work to AI, and they buy it only with an audit trail built in.

    Source: Kalepa

  4. Autonomous freight financing · US · 5 Nov

    Humble Robotics raises a $51M Series A for its cabless electric freight truck

    Obvious Ventures led the round, and Eclipse and Energy Impact Partners invested again. The San Francisco company builds the Humble Hauler, a driverless electric platform with no cab that carries 40 foot or 53 foot containers, with a range of up to 200 miles and a top speed of 55 mph. Customer pilots for container moves at ports and between warehouses are next. Total funding stands at $75M.

    Why it matters: Without a cab, the truck becomes a robot designed for one job: moving containers on short, repeatable routes.

    Source: FreightWaves

  5. Biotech financing · Netherlands · 5 Nov

    Anaheim Bio launches with a €40M Series A to take its CPPD drug into the clinic

    Former Alesta Therapeutics investors Droia Ventures, Frazier Life Sciences, RTW Investments, Novartis Venture Fund, RV Invest and Thuja Capital backed the oversubscribed round. Anaheim Bio, spun out of Alesta in 2026, develops ANA-1, a small molecule that lowers extracellular pyrophosphate to act on the crystal deposits behind calcium pyrophosphate deposition disease. The round carries ANA-1 through IND-enabling studies and into Phase I, with clinical entry expected in 2027.

    Why it matters: CPPD affects an estimated 4 to 7% of adults in Europe and the US, and today’s treatments only manage the inflammation. A drug that acts on the deposits themselves would be a first.

    Source: Drug Discovery World

More deals of the day

AI & semiconductors

  • Bopu Semiconductor (Shanghai) raises several hundred million yuan in a Series B led by Huaying Capital, for silicon photonics chips and optical circuit switches for AI clusters. 6 Nov. Source: Pedaily
  • Trajectory raises a $45M Series A at a $300M valuation led by Sequoia, with Nvidia, Bessemer Venture Partners and Bain Capital Ventures, for a platform that lets lawyers, doctors and other experts retrain open-source models on their own production feedback. 2 Nov. Source: TechCrunch

Energy, planet & space

  • Langu New Energy (Changzhou, China) raises nearly RMB 200M in a Series B+ from a group of industry and regional funds, for solid-state battery electrolytes. 6 Nov. Source: Pedaily
  • Green Voltis (Stockholm) raises a €13.5M Series A led by Lochpine Capital, for AI trading and energy management software that turns battery storage into flexible grid assets. 5 Nov. Source: ArcticStartup
  • Vensum Power (Finland) raises a €9M Series A co-led by Lifeline Ventures, Larsen & Toubro and Eviny Ventures, to bring near lossless power conversion for EV charging, energy storage and AI data centres into mass production in 2027. 6 Nov. Source: Tech.eu

Every earlier day is in the Deals archive.

More news, conversations and analysis on The Briefing.

For information only. Not investment advice.

The Briefing in your inbox

Conversations, deep dives and briefs from the show, free.

Subscribe